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ABSTRACT
Introduction: Increased biochemical bone
turnover markers (BTMs) measured in serum are
associated with bone loss, increased fracture risk
and poor treatment adherence, but their role in
clinical practice is presently unclear. The aim of
this consensus group report is to provide
guidance to clinicians on how to use BTMs in
patient evaluation in postmenopausal osteo-
porosis, in fracture risk prediction and in the
monitoring of treatment efficacy and adherence
to osteoporosis medication.
Methods: A working group with clinical scien-
tists and osteoporosis specialists was invited by
the Scientific Advisory Board of European Soci-
ety on Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskele-
tal Diseases (ESCEO).Enhanced Digital Features To view enhanced digital
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Results: Serum bone formation marker PINP
and resorption marker bCTX-I are the preferred
markers for evaluating bone turnover in the
clinical setting due to their specificity to bone,
performance in clinical studies, wide use and
relatively low analytical variability. BTMs can-
not be used to diagnose osteoporosis because of
low sensitivity and specificity, but can be of
value in patient evaluation where high values
may indicate the need to investigate some
causes of secondary osteoporosis. Assessing
serum levels of bCTX-I and PINP can improve
fracture prediction slightly, with a gradient of
risk of about 1.2 per SD increase in the bone
marker in addition to clinical risk factors and
bone mineral density. For an individual patient,
BTMs are not useful in projecting bone loss or
treatment efficacy, but it is recommended that
serum PINP and bCTX-I be used to monitor
adherence to oral bisphosphonate treatment.
Suppression of the BTMs greater than the least
significant change or to levels in the lower half
of the reference interval in young and healthy
premenopausal women is closely related to
treatment adherence.
Conclusion: In conclusion, the currently avail-
able evidence indicates that the principal
clinical utility of BTMs is for monitoring oral
bisphosphonate therapy.
Keywords: Algorithm; Bone; Bone biomarker;
CTX; Osteoporosis; P1NP; Rheumatology
INTRODUCTION
Osteoporosis—Diagnosis and Burden
of Disease
Osteoporosis is a disease characterized by low
bone mineral density (BMD) and deterioration
of bone microarchitecture, which leads to
increased risk of fragility fracture [1, 2]. Osteo-
porotic fractures, especially of the hip and
spine, commonly result in disability, increased
morbidity and mortality [3]. In 2010, the
number of fractures in the European Union was
estimated at 3.6 million, of which 620,000 were
hip fractures [4]. Patients at high fracture risk
can be identified by investigating known clini-
cal risk factors, which can be combined using a
fracture risk calculator such as FRAX, for the
calculation of 10-year probability of major
osteoporotic and hip fracture [5]. A
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measurement of BMD using dual-energy X-ray
absorptiometry (DXA) provides a good surro-
gate for bone strength and is used to diagnose
osteoporosis, which in postmenopausal women
and men aged C 50 years is defined as a BMD
value of - 2.5 standard deviations (T-score) or
below the mean of the young adult woman
[6, 7]. The estimation of fracture risk probability
in FRAX can be further refined by adding
femoral neck BMD to the clinical risk factors in
the calculation and is recommended in many
clinical guidelines [8].
Measuring Bone Turnover
Bone turnover is necessary to replace damaged
bone, for example, containing microcracks,
with new and healthy bone and to release cal-
cium into the circulation to maintain calcium
homeostasis. Bone resorption comprises the
4–6-week process in which osteoclasts excavate
bone to cause resorption pits, from which
degraded bone releases calcium into the
microenvironment and later the circulation. In
a coupled process, bone resorption triggers bone
formation by osteoblasts, a process taking
4–5 months, which fills the resorption cavity
with an unmineralized osteoid, a connective
tissue rich in collagen. Levels of bone turnover
markers reflect the activity and number of bone-
forming (osteoblasts) and bone-degrading cells
(osteoclasts), providing an estimate of bone
resorption and bone formation. Bone turnover
markers can be measured non-invasively in
either blood or urine at a fairly low cost (usually
\ €20).
The most widely used markers are N-termi-
nal collagen type I extension propeptide (PINP),
osteocalcin and bone alkaline phosphatase for
bone formation and C-terminal cross-linking
telopeptide of type I collagen (bCTX-I), N-ter-
minal telopeptide of type I collagen (NTX),
deoxypyridinoline, hydroxyproline or tartrate-
resistant acid phosphatase isoform 5b (TRAP5b)
for bone resorption (Table 1) [9]. Post-transla-
tional cleavage of type I collagen during bone
matrix formation gives rise to PINP, which
subsequently leaks out into the circulation and
can be measured in serum. Osteocalcin is also
produced by osteoblasts during bone formation,
is excreted by the kidneys and is one of the most
abundant non-collagenous proteins in bone. It
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is also released during bone resorption. Alkaline
phosphatase (ALP) is secreted from bone to the
circulation when the osteoid is mineralized, but
only about half of serum ALP levels are derived
from bone, and the other half emanates mainly
from the liver. However, there are currently
available assays that to a high degree are specific
to the circulating bone ALP isoform (BALP).
Each bone marker has distinct features that
reflect particular aspects of bone physiology. For
example, TRAP5b reflects the number of osteo-
clasts and is not secreted in urine and can
therefore be useful in assessing bone and min-
eral disorder in chronic kidney disease, whilst
measuring bCTX-I in such patients is inappro-
priate since the bone marker accumulates in
serum if renal function is poor. bCTX-I reflects
osteoclast activity resulting in bone degradation
and is useful in evaluating, e.g., glucocorticoid
induced osteoporosis [10], in which bCTX-I
increases rapidly and peaks after about a week
after glucocorticoids are started. Oral glucocor-
ticoid treatment also inhibits bone formation,
as reflected by a rapid and profound decline in
serum osteocalcin levels, whereas the decline in
PINP is considerably smaller [10].
Most clinical trials have used bone turnover
markers to monitor osteoporosis treatment but
the use has not been widely adopted in clinical
practice [11–14]. Factors Affecting Levels of Bone Turnover
Markers
Bone resorption markers, including bCTX-I,
show diurnal variations, with the highest blood
concentration early in the morning and the
lowest at around 2 p.m. Both the levels of bone
resorption and formation markers are sup-
pressed by feeding, but the effect is much larger
for resorption markers (excepted Trap5b),
which are suppressed by 20–40%, whilst for-
mation markers are suppressed by \ 10%
[15, 16]. A fracture normally results in a rapid
increase in bone resorption markers, which
doubles in weeks, followed by more slowly
increasing bone formation markers, which
double in serum levels after about 3 months,
but remain elevated for up to a year after frac-
ture [17]. Several other factors, including glu-
cocorticoids, menopausal state, age, gender,
pregnancy/lactation, aromatase inhibitors,
Table 1 Biochemical bone turnover markers
Measurement medium
Bone formation markers
Bone alkaline phosphatase Serum
PICP Serum
Osteocalcin Serum, urine
PINPa Serum
Bone resorption markers
CTX-Ia Plasma, serum*, urine
ICTP Serum
NTX Serum, urine
Trap5b Serum
Biochemical bone turnover markers that can be measured
in serum are listed. aDenotes bone turnover markers rec-
ommended by IOF and IFCC
PICP procollagen type 1 C propeptide, PINP procollagen
type 1N propeptide, CTX-I carboxyterminal cross-linking
telopeptide of type I collagen, ICTP carboxy-terminal
cross-linking telopeptide of type I collagen, NTX amino-
terminal cross-linking telopeptide of type I collagen,
Trap5b tartrate-resistant acid phosphatase 5b [18]
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Table 2 Controllable and uncontrollable sources of pre-analytical variability in biochemical bone turnover markers
Effect Recommendation Importance
Controllable sources
Circadian
rhythm
High BTM concentrations at night and early
morning, lowest in the afternoon
Collect serum samples in the morning
(7.30–10.00 h)
High
Food intake Decrease in BTMs, especially bone resorption
markers (about 20–40%) after food intake
Collect samples of bone resorption
markers after overnight fast
High
Exercise Intense exercise can decrease bone resorption and
increase bone formation markers
Ask patient to refrain from intense
exercise the day prior to blood
sampling
Low
Alcohol
intake
Alcohol consumption decreases BTMs Ask patient to refrain from excessive
alcohol intake the day prior to blood
sampling
Low
Seasonal Higher levels of BTMs in winter In research, take samples in the same
season or adjust for seasonal variation
Low
Medications
-oral GC Rapid and dose-dependent decrease in bone
formation markers, small effect on bone
turnover markers
Consider dose of oral GC High
-aromatase
inhibitors
Increase in BTMs
Uncontrollable sources
Age Postmenopausal women have higher BTMs than
premenopausal women
Use age-based reference intervals High
Bed rest/
immobility
Bone resorption markers increase and formation
markers decrease
Consider different expected baseline level
when evaluating BTMs
High
Ethnicity Small differences. Lower osteocalcin in African
Americans vs. Caucasians
Unclear if different reference intervals
are needed for different ethnicities
Low
Fracture BTMs increase after fracture, with maximum
effect 2–12 weeks, but remains elevated up to
52 weeks
Limits evaluation in patients with recent
fracture
High
Menopause BTMs increase at the time of the final menstrual
period
Use reference intervals considering
menopausal status
Moderate
Selected factors affecting the pre-analytical variation in bone turnover markers (BTMs) [9, 22]
GC glucocorticoids
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renal insufficiency, immobility and exercise,
have an impact on blood-bone turnover mark-
ers and should also be considered in their eval-
uation (Table 2) [18].
Current Recommendations of Use of Bone
Turnover Markers in Clinical Guidelines
The use of serum bone formation marker PINP
and resorption marker bCTX-I in the investiga-
tion of osteoporosis or in monitoring treatment
is currently recommended in several guidelines
around the world, including those issued by the
UK National Osteoporosis Guideline Group
(NOGG), by the National Osteoporosis Foun-
dation in the US [19–21] and by the Interna-
tional Osteoporosis Foundation (IOF) [22, 23].
Aim
The aim of this consensus group report is to
provide guidance, based on the opinion of the
experts of this group, to clinicians on how to
use bone turnover markers in patient evalua-
tion, in fracture risk prediction and in moni-
toring treatment effect and adherence to oral
bisphosphonates in postmenopausal osteo-
porosis. The results of this report are endorsed
by the Scientific Board of the European Society
on Clinical and Economic Aspects of Osteo-
porosis, Osteoarthritis and Musculoskeletal
Diseases (ESCEO).
METHODS
An international working group was gathered to
develop recommendations for the use of bone
turnover markers in the diagnosis and treat-
ment of osteoporosis. Specialists in internal
medicine, endocrinology, rheumatology, reha-
bilitation, geriatrics, clinical biochemistry and
epidemiology were invited to participate by the
Scientific Advisory Board of European Society
on Clinical and Economic Aspects of Osteo-
porosis, Osteoarthritis and Musculoskeletal
Diseases (ESCEO). A 1-day in-person meeting
was held on 5 February 2019 in Geneva to dis-
cuss the existing scientific literature on the
topic and to propose recommendations. After
the meeting, members of the writing group
(ML, JYR, JK, EM) drafted the first manuscript
with the recommendations. The manuscript
was then reviewed and commented on by all
group participants from the Geneva meeting.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS AND DISCUSSION
Preferred Bone Markers
The IOF and International Federation of Clini-
cal Chemistry and Laboratory Medicine recom-
mend that the bone formation marker PINP and
resorption marker bCTX-I be used as reference
markers and measured in serum using stan-
dardized assays. These markers were chosen
based on a number of criteria, including ade-
quate characterization of the marker, specificity
to bone, performance in clinical studies, bio-
logical and analytical variability, wide avail-
ability, potential for standardization of
methods, sample handling, stability and med-
ium of measurement (serum vs. urine) [22–24].
The Role of Bone Turnover Markers
in the Diagnosis of Osteoporosis
and Patient Evaluation
Osteoporosis is operationally defined by BMD
using DXA. There is an inverse relationship
between BMD and the serum levels of bone
turnover markers, but the correlation is weak to
moderate [25]. In the TRIO study, only 20% of
postmenopausal women, diagnosed with
osteoporosis using DXA had serum bCTX-I
above the upper normal range for healthy pre-
menopausal women [26]. Therefore, bone
turnover markers cannot be used for the diag-
nosis of osteoporosis. However, abnormal levels
of bone turnover markers, particularly when
high, can be useful for identifying patients in
whom further investigations may be needed to
detect secondary causes of osteoporosis (e.g.,
2816 Adv Ther (2019) 36:2811–2824
primary hyperparathyroidism, thyrotoxicosis,
malabsorption) or other bone diseases (e.g.,
osteomalacia, Paget’s diseases, bone metastases,
multiple myeloma) [27].
Predicting Bone Loss Using Bone Turnover
Markers
Declining circulating estradiol levels, particularly
during the menopausal transition, gives rise to
increased bone turnover due to an increased
number of bone remodelling units with a greater
increase of osteoclastic activity, causing an
imbalance between bone resorption and forma-
tion, leading to bone loss. The increased bone
turnover is reflected by an increase in bone turn-
overmarkers,which is associatedwith loss ofboth
trabecular and cortical bone [28, 29]. Bone turn-
over marker levels correlate with bone loss on a
group level, and this correlation can be strength-
ened by sampling blood on several occasions to
reduce the between-samples variation. However,
the proportion of the variation in BMD change
that can be explained by bone turnover markers
remains quite small. Thus, predicting an individ-
ual’s bone loss over time using bone turnover
markers has proved challenging and cannot be
recommended in a clinical setting [30–32]. Since
bone loss from the forearm and hip has been
associated with increased risk of fracture, it seems
reasonable to assume that bone turnovermarkers,
which are associated with bone loss, can predict
fractures [33, 34]. In addition, bone turnover
markers may affect fracture risk independently of
BMD. Increased bone turnover can be accompa-
nied by a high proportion of newly formed and
partly mineralized bone, which is weaker than
mineralized bone, and poor trabecular bone
microstructure, because of resorption cavities on
the trabeculae, trabecular perforations and loss of
trabecular connectivity, can have a substantial
negative impact on bone strength, not captured
with DXA [35, 36].
The Role of Bone Turnover Markers
in Fracture Risk Prediction
Most prospective studies investigating the
associations between bone turnover markers
and incident fractures in postmenopausal and
older women have found that the higher the
level of bone turnover markers, the greater the
fracture risk [18]. With some exceptions, bone
resorption markers and bone alkaline phos-
phatase are more strongly associated with frac-
tures (all, multiple, spine and hip) than other
bone turnover markers [32, 37–39]. Elevated
bone turnover markers increase fracture risk
independently of BMD in some but not in all
studies [18]. The role of serum PINP and bCTX-I
in fracture prediction was investigated in a
meta-analysis of six prospective cohorts with
women and men. The risk of fracture was
increased by 23% [hazard ratio 1.23 (95% CI
1.09–1.39)] and 18% [hazard ratio 1.18 (95% CI
1.05–1.34)] per SD increase in serum PINP and
bCTX-I, respectively, but these analyses were
not adjusted for BMD [40]. In a recent meta-
analysis of nine studies of mostly post-
menopausal women, bone turnover markers
were weakly associated with fracture risk after
adjustment for confounders, with a gradients of
risk of 1.20 for serum bCTX-I and of 1.28 for
serum PINP. It was concluded that PINP and
bCTX-I appear to predict fracture risk indepen-
dently of BMD and clinical risk factors [41], but
the availability of knowledge of confounding
variables was very variable. Bone turnover
markers’ ability to predict fractures seems to be
stronger over short (within a few years) rather
than long time periods [42, 43], which likely
limits their value and usefulness in long-term
fracture prediction in risk calculators such as
FRAX, but makes them more appealing in the
prediction of short-term or imminent fracture
risk. Based on the relatively weak associations
between bone turnover markers and fracture
risk, uncertainty about the independent ability
to predict fractures, the natural variability in the
markers, problems with the assays and the
inability to predict fracture over long time
periods, the Fracture Risk Assessment Tool
(FRAX) Position Development Conference
members concluded that bone turnover mark-
ers should not be included in the calculation of
the 10-year probability of fracture in the FRAX
tool [44].
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The Use of Bone Turnover Markers
in the Monitoring of Osteoporosis
Treatment
Bisphosphonates
Bisphosphonates, including alendronate, rise-
dronate, zoledronate and ibandronate, are the
most commonly used medications to treat
osteoporosis [4]. They reduce bone resorption
by inhibiting osteoclasts, increase BMD and
lower the risk of spine, hip and non-vertebral
fractures [45–47]. With treatment in recom-
mended doses, bCTX-I is reduced rapidly, by
approximately 50–80%, reaching maximum
suppression after about 2 months, whilst PINP
suppression is slightly smaller and reaches its
nadir after about 6 months [48].
Several clinical trials have reported a rela-
tionship between the reduction of bone turn-
over markers and the reduction in vertebral and
nonvertebral fracture risk following anti-re-
sorptive treatment [18]. For example, changes
in bone turnover markers have been shown to
explain a considerable proportion, 54–77%, of
the nonvertebral fracture risk reduction with
risedronate treatment [49]. The 12-month
decrease in bCTX-I and PINP with alendronate
treatment in the Fracture Intervention Trial was
associated with the reduction of spine fractures
[50]. However, due to low sensitivity, it has
been deemed inappropriate to use bone turn-
over markers to predict an individual patient’s
response to treatment [51].
Another complicating factor is that the effect
on bone marker suppression varies across the
licensed bisphosphonates. For example, in the
TRIO study, alendronate and ibandronate
treatment given to postmenopausal osteo-
porotic women caused a greater suppression of
bCTX-I and NTX-I levels than risedronate [26].
A major challenge with oral bisphosphonates
is the poor adherence with less than half of
patients taking medication 1 year after treat-
ment initiation [52]. Women adhering to oral
bisphosphonates have greater reductions in
serum bone turnover marker levels and lower
fracture risk than women with poor adherence
[26]. It has therefore been proposed that bone
turnover markers can be used to monitor treat-
ment adherence. For such a task to be successful
and clinically useful, clear definitions of what
constitutes an adequate response to treatment
must exist. A blood test prior to and after a
certain time post-treatment initiation will be
required to determine the level of change in the
bone turnover markers. Since serum PINP and
bCTX-I are responsive to treatment and have
low within-subject variability, their use is rec-
ommended. A commonly proposed approach to
determine if the change in the bone marker is
physiologically relevant (and not due to mea-
surement or sampling error) is to compare the
observed change with the least significant
change (LSC). Assuming that the change is
normally distributed, a true change would have
to be greater than the LSC, which equals
H2 9 1.96 9 intra-individual coefficient of
variation (CV) = 2.77 9 CV. For example, using
this approach, serum bCTX-I would need to
drop from 350 ng/l to 259 ng/l, assuming an
intra-individual CV of 9.4%, which corresponds
to an LSC of 26%, in a treated patient to confirm
a positive treatment response. In the TRIO
study, 3-month bisphosphonate treatment
resulted in suppression of PINP and bCTX-I
larger than LSC in 75–94% and 68–73%,
respectively, of the included women. A detec-
tion level, describing the proportion of patients
taking oral bisphosphonates that show decrea-
ses (larger than LSC) in each of the markers,
bCTX-I and PINP, was investigated and was
found to be 84% for PINP, 87% for bCTX-I and
as high as 94% when measuring both markers
[26, 53]. Based on the findings of the TRIO
study, the International Osteoporosis Founda-
tion (IOF) and European Calcified Tissue Society
(ECTS) Working Group recently issued a rec-
ommendation to monitor oral bisphosphonate
treatment using a baseline and 3-month mea-
surement of serum bCTX-I and PINP. According
to this recommendation, if the decrease is
smaller than the LSC, the treating clinician
should reassess to identify problems with treat-
ment, which usually relate to poor adherence
(Fig. 1) [53].
Another approach that has been proposed is
to define the target for treatment as suppression
of the bone turnover marker to the lower half of
the reference interval in young and healthy
premenopausal women [54]. This strategy is
2818 Adv Ther (2019) 36:2811–2824
complicated by the fact that not all women are
above this interval prior to receiving treatment.
If bone turnover markers have not been mea-
sured prior to starting therapy, the reference
interval method could still be used, which
increases the clinical usefulness of the method.
An analysis from the TRIO study revealed that
the proportion of responders detected using the
reference interval approach was very similar to
the one detected using the LSC approach [26].
Denosumab
Denosumab is a human monoclonal antibody
to RANKL, which is administrated subcuta-
neously. It is the most potent inhibitor of bone
resorption, as reflected by a very rapid decrease
to nearly undetectable levels of bone resorption
marker bCTX-I within a few days of adminis-
tration [55]. Serum PINP is also suppressed by
denosumab treatment, but the decrease is not as
marked as for bCTX-I and takes up to 3–-
6 months to be complete [56]. Biannual injec-
tions of denosumab reduce the risk of hip,
vertebral and non-vertebral fractures in post-
menopausal women [13]. The effect of deno-
sumab is more potent than bisphosphonates in
increasing BMD, which continues to rise for up
to 10 years of treatment [57]. However, when
treatment is stopped, there is a rebound
increase in bone turnover markers well above
pre-treatment levels and accelerated bone loss is
seen [58]. During this phase the risk of multiple
vertebral fractures increases [59, 60]. Pretreat-
ment with bisphosphonates reduces this over-
shoot in bone turnover markers when
denosumab treatment stops, and starting bis-
phosphonate therapy after denosumab cessa-
tion is able to attenuate bone loss, but the
optimal regime for bisphosphonate therapy
after denosumab cessation has not yet been
determined [61]. It is possible that monitoring
the bone marker response may aid in the use of
bisphosphonate treatment frequency and dos-
ing when denosumab treatment is stopped.
Future research is needed to address this
hypothesis.
Anabolic Treatment
Treatment of postmenopausal women with the
parathyroid hormone analogue teriparatide
causes a rapid, within days, response in bone
formation markers such as PINP, which reach
peak levels after 3 months [62, 63]. This increase
Fig. 1 Algorithm proposed by an IOF-ECTS working group for monitoring bisphosphonate treatment adherence using
CTX-I and/or PINP [53]
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is followed several months later by a consider-
ably smaller rise also in bone resorption mark-
ers. The response to teriparatide is dose-
dependent and the increase in PINP correlates
weakly or moderately with increases in BMD,
which are considerably larger at bone sites rich
in trabecular bone, such as the lumbar spine,
than those seen with bisphosphonate therapy
[64, 65]. Teriparatide is more effective than oral
risedronate in reducing the risk of vertebral and
clinical fractures in postmenopausal with severe
osteoporosis [66]. A systematic review of the
present evidence concluded that there is insuf-
ficient evidence to recommend the use of
monitoring bone turnover markers for predict-
ing the effect of teriparatide treatment effect
[67].
CONCLUSION
Although the use of bone turnover markers has
been extensive in clinical trials, prospective
cohort studies, case-control studies and at many
clinics included in standard patient evaluation
for many years, their value in clinical practice is
not entirely clear. Challenges relating to large
pre-analytical (diurnal variations, feeding, age,
gender, menopausal status, etc.) and analytical
variations and use of a multitude of markers in
different clinical scenarios have impaired the
interpretation of their value and makes recom-
mendations for their use in the individual
patient more difficult. Despite these challenges,
this working group recommends that the fol-
lowing conclusions can be made, based upon
the available evidence:
• The bone formation marker serum PINP and
resorption marker serum bCTX-I are the
preferred markers for evaluating bone turn-
over in the clinical setting.
• Bone turnover markers cannot be used to
diagnose osteoporosis but can be of value in
patient evaluation and can improve the
ability to detect some causes of secondary
osteoporosis.
• Serum bCTX-I and PINP correlate only mod-
erately with bone loss in postmenopausal
women and with osteoporosis medication-
induced gains in BMD. Therefore, the use of
bone turnover markers cannot be recom-
mended to monitor osteoporosis treatment
effect in individual patients.
• Adding data on serum bCTX-I and PINP
levels in postmenopausal women can only
improve fracture risk prediction slightly in
addition to clinical risk factors and BMD and
therefore has limited value.
• Bisphosphonates are the most commonly
used osteoporosis medications, but adher-
ence to oral bisphosphonates falls below
50% within the first year of treatment.
Monitoring PINP and bCTX-I is effective in
monitoring treatment adherence and can be
defined as the sufficient suppression of these
markers (by more than the LSC or to the
lower half of the reference interval for young
and healthy premenopausal women).
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